Glenn D. Prestwich to speak at 7th Modern Drug Discovery Summit Oct 19-21 2011 in San Diego, CA
Glenn D. Prestwich, Director of the Therapeutic Biomaterials Center, Special Presidential Assistant for Faculty Entrepreneurism and Presidential Professor of Medicinal Chemistry at University of Utah, will give a plenary keynote presentation on “Engineering a Clinical Biomaterial for Regenerative Medicine: From Bench to Business” at the 7th Modern Drug Discovery and Development Summit to be held in San Diego, CA on October 19-21, 2011 by GTC.
Andreas Marzinzik at Novartis to Speak at Drug Design Medicinal Chemistry Meeting Oct 19 2011, Cali
Andreas Marzinzik, Director of Exploratory Medicinal Chemistry and Global Discovery Chemistry at Novartis Institutes for BioMedical Research, will give a presentation on “Novel Approaches to Inhibit Kinases: The IGF1R Case” at the 5th Drug Design and Medicinal Chemistry Conference to be held in San Diego, CA on October 19-21, 2011 by GTC.
Dr. Jon Heinrichs, Director, Microbial Vaccines, Merck Research Laboratories, to Deliver Featured Speech at 9th Annual Vaccines Discovery and Development: All Things Considered Conference (Nov. 7-8, 2011, in Boston, MA)
Dr. Heinrichs will discuss the development of vaccines for the prevention of Chlamydia trachomatis genital infections. Chlamydia trachomatis is a leading cause of both ocular disease (trachoma) and urogenital infections, and is the most commonly reported sexually transmitted disease in the United States. Although genital infection with chlamydia is frequently asymptomatic, failure to treat women can lead to serious health conditions including pelvic inflammatory disease and infertility. Merck, in collaboration with the University of Texas Health Sciences Center and the University of Texas at San Antonio, is seeking to identify novel vaccine candidates from the proteome of this organism.
Dr. Joseph Joyce, Director, Vaccine Research, Merck Research Laboratories, to Deliver Featured Speech at 9th Annual Vaccines Discovery and Development: All Things Considered Conference (Nov. 7-8, 2011, in Boston, MA)
Dr. Joseph Joyce will discuss M-Protein-derived peptide conjugate vaccine candidates for Streptococcus pyogenes. Group A Streptococcus (GAS) infections caused by S. pyogenes represent a major health care burden in both developed and developing nations. Disease etiology ranges from mild pharyngitis to life-threatening manifestations such as necrotizing fasciitis and toxic shock syndrome. In a percentage of individuals, post-infection sequelae can lead to serious autoimmune manifestations such as rheumatic fever and glomerulonephritis. While first line antibiotics are generally effective, recurrent infection and limited accessibility to therapeutics in the developing world where incidence of severe disease is highest drive the need for prophylactic vaccine development.
Dr. Philip Dormitzer, Head at Novartis, to Speak at Vaccines Meeting on Nov. 7-8 in Boston, Ma.
Dr. Philip Dormitzer, Head, Viral Advanced Programs Global Program Team, Novartis Vaccines and Diagnostics, to deliver featured presentation at the “9th Annual Vaccines Discovery and Development: All Things Considered” conference, to be held on Nov. 7-8, 2011 in Boston, MA by GTC.
Erik Henchal, Associate Director at FDA to Speak at Vaccines Meeting on Nov. 7-8 in Boston, MA
Dr. Erik Henchal, Associate Director, Management and Scientific Affairs, Office of Vaccine Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, to deliver featured speech at “9th Annual Vaccines Discovery and Development: All Things Considered” conference, to be held on Nov. 7-8, 2011 in Boston, MA by GTC.
Shafique Virani, Global Head of CNS Business Development & Licensing at F. Hoffmann-La Roche, to give featured presentation at 4th CNS Partnering and Deal-making Conference (Sept 22-23, 2011 in San Francisco, CA)
Shafique Virani, Global Head of CNS Business Development & Licensing at F. Hoffmann-La Roche will give a featured presentation on “Partnering in Neurodegenerative Diseases: The Roche-Remynd Deal” at the 4th CNS Partnering and Deal-making Conference to be held in San Francisco, CA on September 22-23, 2011 by GTC.
Nigel Mcmillan, Principal Research Fellow and Deputy Director, University of Queensland Diamantina Institute, Will Give Featured Presentation at Gtc’s 2nd Rnai Research & Therapeutics Conference, San Francisco, Ca, July 7-8, 2011
Nigel McMillan, Principal Research Fellow and Deputy Director, University of Queensland Diamantina Institute, will give a featured presentation titled “RNAi Therapy and the Immune system – A Good Thing?” at GTC’s 2nd RNAi Research & Therapeutics Conference on July 7-8, 2011 in San Francisco, CA
Martyn Banks, Executive Director, Molecular Sciences and Candidate Optimization, Bristol Myers Squibb, Will Give a Featured Presentation at Gtc’s 6th Assay & Drug Discovery Technologies Conference, San Francisco, Ca, July 7-8, 2011
Martyn Banks, Ph.D., Executive Director, Molecular Sciences and Candidate Optimization, Bristol Myers Squibb, will give a featured presentation titled “The Impact of Screening on Drug Discovery at Bristol Myers Squibb” at GTC’s 6th Assay & Drug Discovery Technologies Conference on July 7-8, 2011 in San Francisco, CA.
Susan Abushakra, Vice President of Global Development, Program Lead for Alzheimer’s Disease at Elan Pharmaceuticals, to Give Featured Presentation at 5th Neurodegenerative Conditions Research and Development (Sept 22-23, 2011 in San Francisco)
Susan Abushakra, Vice President of Global Development, Program Lead for Alzheimer’s Disease at Elan Pharmaceuticals will give a featured presentation on “ELND005 (Scyllo-inositol) an Amyloid Anti-aggregation Agent: What We Learned in Phase 2 Studies” at the 5th Neurodegenerative Conditions Research and Development Conference to be held in San Francisco, CA on September 22-23, 2011 by GTC.